论文部分内容阅读
目的探讨复发卵巢癌卡铂腹腔温热化疗联合多西他赛全身化疗的疗效和毒副作用。方法将70例Ⅲ～Ⅳ期复发卵巢癌患者按随机原则选择35例作为治疗组,采用卡铂腹腔温热化疗联合多西他赛全身化疗;35例作为对照组,采用卡铂联合多西他赛全身化疗,并对两组化疗后1,3,5年生存率及毒副作用对照研究,并经统计学χ2检验。结果治疗组1,3,5年生存率分别为88.6%(31/35)、65.7%(23/35)和37.1%(13/35),对照组分别为80.0%(28/35)、51.4%(18/35)和22.9%(8/35),两组比较差异无显著性(P<0.05)。毒副作用主要是骨髓抑制,白细胞下降率(Ⅲ～Ⅳ度)分别为5.7%(2/35)和31.4%(11/35,P<0.05)。结论复发卵巢癌卡铂腹腔温热化疗联合多西他赛全身化疗的疗效优于卡铂联合多西他赛全身化疗,且毒副作用轻,有利于提高患者的生存率及生存质量。
Objective To investigate the curative effect and side effects of carboplatin peritoneal hyperthermia combined with Docetaxel systemic chemotherapy in patients with recurrent ovarian cancer. Methods Seventy patients with stage Ⅲ-Ⅳ ovarian cancer were randomly divided into treatment group (n = 35) treated with carboplatin peritoneal hyperthermia combined with docetaxel systemic chemotherapy. 35 patients were treated with carboplatin combined with docetaxel Race systemic chemotherapy, and 1, 3, 5-year survival rate and toxic side effects after two groups of chemotherapy control study, and the statistical χ2 test. Results The 1, 3, 5-year survival rates were 88.6% (31/35), 65.7% (23/35) and 37.1% (13/35) in the treatment group and 80.0% (28/35) in the control group and 51.4 % (18/35) and 22.9% (8/35) respectively. There was no significant difference between the two groups (P <0.05). The main side effects were myelosuppression. The rates of leukopenia (Ⅲ ~ Ⅳ) were 5.7% (2/35) and 31.4% (11/35, P <0.05) respectively. Conclusions The efficacy of carboplatin peritoneal hyperthermic chemotherapy combined with docetaxel chemotherapy in the treatment of recurrent ovarian cancer is better than that of carboplatin combined with docetaxel chemotherapy. The toxicities and side effects of carboplatin plus cisplatin are beneficial to improve the survival rate and quality of life.